TPM3 and non-small cell lung carcinoma: It revealed the antitumor effect of crizotinib for NTRK fusion-positive NSCLC, suggesting that combining EGFR-TKIs and TRK inhibitors may be an optional treatment for patients with NTRK fusion-mediated EGFR-TKI resistance.